INTRODUCTION
Although secreted by monocytes (1) , and present in large amounts in lysosomes of polymorphonuclear leukocyte(s) (PMN)l (2), the function of lysozyme in inflammatory and immune responses is largely unknown. Since its discovery as a bacteriolytic factor in 1922 (3), a role for lysozyme in host defenses has been Address reprint requests to Dr. Jacob, University of Minnesota Hospitals, Minneapolis, Minn. Received for publication 30 October 1978 and in revised form 8 March 1979. 1Abbreviations used in this paper: PMN, polymorphonuclear leukocyte(s); tri-NAG, trisaccharide of N-acetylglucosamine.
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suggested by some (3, 4) , but questioned by others (5-7), mainly because most pathogenic bacteria are insensitive to its lytic activity (3, (8) (9) (10) in the absence of other enzymes, antibody and complement. Recently, lysozyme has been shown to alter the shape and adherence of mammalian cells in culture (11) , raising the possibility that it may somehow serve as a regulator of membrane phenomena. Thus far, the identity of its target substrate in mammalian cells remains unknown.
The fact that lysozyme is secreted by phagocytes suggested that investigation of its effects on inflammatory cells themselves might be profitable. Monocytes continuously secrete lysozyme (1) and migrate relatively late to areas of inflammation-well after PMN . From this pattern, we hypothesized that lysozyme might modulate PMN membrane function so as to diminish excessive tissue injury attendant to PMN phagocytic activity. Indeed, the results of the present studies which have been published in preliminary form elsewhere (12) demonstrate that human lysozyme, but not its closely similar analogue obtained from hen eggwhite, is a potent inhibitor of chemotaxis and of the production oftoxic oxygen radicals by stimulated PMN.
METHODS
Neutrophil isolation. Neutrophils obtained from normal laboratory personnel were purified in different ways for different studies. For chemotaxis assays, heparinized blood was allowed to sediment at 37°C in a 5% CO2 atmosphere, and the resulting buffy coat was washed once and suspended in the appropriate media. For all other experiments, neutrophils were purified by the Ficoll-Hypaque centrifugation technique (13) . Heparinized (5 Volume 64 July 1979 226-232 water for 20 s followed by reconstitution to isotonicity with 3.6% sodium chloride. The leukocytes were resuspended in a small volume of Hanks' balanced salt solution containing 0.5% human serum albumin and then layered onto a FicollHypaque (Pharmacia Fine Chemicals, Piscataway, N. J.) gradient, centrifuged at 400 g at 40°C for 30 min, washed twice, and finally resuspended to appropriate concentration in Hanks' balanced salt solution containing 0.5% human serum albumin or the appropriate media. The resulting preparations were 95-99% neutrophils and free of erythrocytes and their ghosts.
Lysozyme. Human lysozyme was isolated from the urine of patients with monocytic and myelomonocytic leukemia with a bentonite absorption technique (14) . By sodium dodecyl sulfate gel chromatography ( Fig. 1) the purified lysozyme showed a major component in the molecular weight range of 15,000-daltons and a trace unidentified component in the 30,000-dalton range. It is possible that this contaminant is a dimer of lysozyme, but this has not been determined. Purified hen eggwhite lysozyme was obtained from Sigma Chemical Co., St. Louis, Mo.
Inhibitors oflysozyme. Antiserum to human lysozyme was prepared in rabbits as described (14) . This antiserum produced a single precipitin line by immunodiffusion with human lysozyme but did not react with eggwhite lysozyme. The trisaccharide of N-acetylglucosamine (tri-NAG) was generously supplied by Dr. Gustave E. Leinhard. tri-NAG irreversibly inhibits the enzymatic activity of both human and eggwhite lysozyme by blockage of the active site (7) .
Chemotaxis studies. The agarose chemotaxis assay was slightly modified from that described by Nelson et al. (15); i.e., agarose (Litex, Denmark) was used in place of indubiose. Each agarose chemotaxis plate consisted of six triplets of wells cut with a template in radial fashion. A pooled sample of heat-inactivated human serum was placed in the inner wells to assess random migration of buffy coat cells. These cells, suspended in 10 times minimal essential media with Earl's balanced salt solution and adjusted to pH 7.4, were placed in the center wells at a concentration of 2.5 x 107/ml. The different chemotaxins (described below) were placed in outer wells and the plates incubated at 37°C in a 5% CO2 atmosphere for 3 h. The distance from the outer edge of the center wells to the leading border of migrating cells was measured with a microprojector. We confirmed the observation of Nelson et al. (15) that neutrophils make up the majority of migrating cells during the 3-h period of observation. In 68,000 mol wt ---47,000 nmol wt ---21,500 mol wt , 15 ,000 mol wt SDS-PAGE FIGURE 1 Sodium dodecyl sulfate gel electrophoresis of purified human lysozyme obtained from urine of patients with monocytic leukemia. There is one major band with -14,500 mol wt, and a very faint band with _30,000 mol wt. some experiments Ficoll-Hypaque purified neutrophils, rather that whole buffy coat preparations, were used. The chemotaxins used were zymosan-activated serum, culture filtrates of Escherichia coli, and the synthetic dipeptide N-formylmethionylphenylalanine. The zymosan-activated serum and E. coli filtrates were prepared as described (16, 17) ; the synthetic dipeptide, generously supplied by Dr. Robert Nelson, was used at a concentration of 0.1 ,uM, a level previously shown to promote maximal chemotaxis in the agarose system.
The effects of lysozyme on neutrophil chemotaxis was tested by preincubating the cells with various concentrations of human, or eggwhite, lysozyme, or with media alone, for 30 min in a shaking 370C water bath before assay. In other experiments, lysozyme was added directly to zymosanactivated serum (not to cells), incubated for 30 min at 37°C, and used as the chemotaxin in the outer well of the agarose system. When appropriate, we incubated the lysozyme inhibitor, tri-NAG, with lysozyme and neutrophils for 30 min at 37°C before placing the mixtures in the center wells.
Inflammatory skin exudates. Rebuck (18) skin windows were constructed on the shaved backs of anesthetized male guinea pigs by abrading 2 cm contiguous areas of skin with a sterile scalpel. 0.1 ml of human or egg white lysozyme (500 ,ug/ml) was placed on one area, and media on the other. Glass coverslips were secured and removed at 30-min intervals for 5-h, with replacement oflysozyme or media at each change.
Oxygen metabolism ofPMN. Oxidation ofglucose by PMN via the hexose monophosphate shunt was assayed with 1-_4C-labeled glucose as described (19) . Purified neutrophils were suspended at a concentration of 4 x 106/ml in medium 199 and incubated in 25 ml Erlenmeyer flasks with 100 ,tCi of 1-14C-labeled glucose (New England Nuclear, Boston, Mass.) either with or without methylene blue added to give maximum hexose monophosphate shunt stimulation. When appropriate, human or eggwhite lysozyme was added to final concentration of 500 ,ug/ml. After incubation for 2 h at 37°C in a shaking water bath, perchloric acid was added; evolved 14C-labeled CO2 was trapped in 0.3-ml of Hyamine (Rohm and Hass, Philadelphia, Pa.) in plastic center wells suspended over the cell suspension and counted after solubilization in 10 ml of scintillation fluid in a Beckman scintillation counter (Beckman Instruments, Inc., Spinco Div., Palo Alto., Calif.).
Superoxide anion was measured by cytochrome c assay as described by Goldstein et al. (20) . The specificity of cytochrome c reduction assay was determined by treating the reaction mixtures with 10 ,ug/ml of superoxide dismutase; the superoxide dismutase-inhibited superoxide generation was expressed as nanomoles of cytochrome c reduced per
Ancillary studies. PMN phagocytosis was assayed by a modification ofthe cophagoeytosis methods of Chang (21), and Cannarozzi and Malawista (22) using serum-opsonized zymosan particles suspended in media containing 125I-serum albumin. In this technique, the 125I-labeled albumin is incorporated into the cells when they phagocytose the opsonized particles, and intracellular radioactivity of washed PMN serves as a measure of phagocytic activity. Cyclic AMP was measured as described by Hatch et al. (23) . Cell viability was monitored by trypan blue dye exclusion and lactate dehydrogenase release (24) . by human, but not eggwhite, lysozymle (Fig. 2) . Signlificant inhibition was noted over the coniceintration range, 10-1,000 ,ug/ml, and was evident when either activated complement (Fig. 2, left) , E. coli culture filtrates (Fig. 2, right (Fig. 3) . In separate experiments (not shown) we found eggwhite lysozymne had no effect on the skinl inflacmml-tatory responise and also conifirmed that neither lysozyme preparation altered the ability of PMN to adhere to the glass coverslips used in these studies.
RESULTS

Effects
Effects of lysozyme on oxidative metabolism of PMN. Human lysozyme significantly inhibited the burst of hexose monophosphate shunt metabolism caused by incubating PMN with methylene blue (Fig. 4, left) but did not suppress resting metabolic activity (not shown). Human lysozyme also inhibited the production of superoxide anion by PMN stimulated by opsonized zymosan particles (Fig. 4, right) and phorbol myristate acetate, (Table II) . However, once triggered by either stimulus, superoxide anioni production could not be shut off, even when human lysozyme was added within 1 min of the triggering stimulant (Table II) . That inhibition of superoxide anion production by phagocytosing PMN did not result fromnca suppression of phagocytosis by human lysozyme was validated by electron microscopic examination of granulocytes during their phagocytosis of opsonized zymosan particles. In anicillary cophagocytosis studies, which permits semiq(uantitation of phagocytosis (21, 22) , human lysozyme actually slightly potenitiated (by 10-20%; P < 0.01) the phagocytic capacity of PMN towardl opsoniized zymosani particles. f F s ' ; 9 ' ' ' ' e ' < s ' t . ' > ' o " ' z ? ' : ' r ' 4 < . t . . . 9 a x t . J I r : ; Reversal of human lysozyme effects on PMN by specific inhibitors. Lysozyme interacts specifically with p1-4 glycosidic linkages on bacterial cell walls (25) , and oligosaccharide derivatives of these cell walls can bind irreversibly to lysozyme and prevent, thereby, its lytic effects on Micrococcus luteus (26) . One such oligosaccharide, a trisaccharide of N-acetylglucosamine, acts as a specific substrate inhibitor of lysozyme (26) and strikingly suppressed the observed effects of human lysozyme on PMN function. The inhibition of PMN chemotaxis by human lysozyme was reversed (albeit not completely) if tri-NAG was added at a concentration of 0.5 mM before the human lysozyme (500 ug/ml) (Table III) ; tri-NAG alone had no effect on PMN movement (not shown). The inhibition by human lysozyme of triggered PMN superoxide generation was also blocked by tri-NAG (Table III) . Rabbit antibody to human lysozyme also reversed the inhibition of superoxide anion generation by lysozyme treated PMN (Table III) . Neither tri-NAG nor antilysozyme affected superoxide anion generation when added alone (not shown).
Effects ofhuman lysozyme on PMN cyclic AMP levels. (27) may serve as a regulator of inflammatory events is an intriguing one. By inhibiting cell movement, lysozyme may serve to both limit further PMN accumulation and to trap cells already present at the inflammatory site -effects that might serve to decrease tissue injury attendant to inflammation. This suggested protective effect of lysozyme would be potentiated by its concomitant ability to suppress formation of toxic oxygen radicals whose accumulation would also be damaging to tissues. Because these activities, which in concert appear to quiet the inflammatory response, are promulgated at concentrations of lysozyme extant in inflammatory exudates -10-125 ,ug/ml (27, 28) The mechanism by which lysozyme quiets PMN is unclear, but we postulate that the plasma membrane is the site of its action. That lysozyme can affect mammalian membranes in other systems has been documented by observations that it alters the surface morphology of transformed human hepatocytes in culture (11) , and that it agglutinates rat mitochondria by interacting with their membranes at sites which also bind concanavalin A (29) . In the present studies we have shown that extensive washing of PMN (38) . Because lysozyme was itself not found to be chemotactic (Table I) , its mechanism of inhibition is evidently not that of deactivation. In addition, chemotactic factor inactivators in normal serum have been described (39, 40) that inactivate complement-derived chemotactic fragments. It appears that human lysozyme is also distinct from these inactivators in that its addition to complement-activated serum causes no alteration in chemotaxis (Table I) .
Finally, cyclic nucleotides evidently play an important role in PMN locomotion (41, 42) . Inhibitors of chemotaxis generally have been found to increase intracellular cyclic AMP levels (23) . Thus, we find it somewhat surprising that neither human or eggwhite 230 Gordon, Douglas, Kay, Yamada, Osserman, and Jacob lysozyvme affect basal or stimulated PMiN eyelic AMP levels. The exact mechanism by which human lysozyme inhibits PMIN chemotaxis remains for further study. Production of activated oxygen compounds (20) , another membrane-dependent function of PMN, was also found to be inhibited by human, but not eggwhite, lysozyme. However, when lysozyme was added as briefly as 1 min after any of several diverse stimulants of free radical production (e.g., opsonized zymosan particles, phorbol imyristate acetate, or methylene blue) its inhibiting effect was lost (Table II) . It therefore appears that lysozyme inhibits superoxide generation directly and does not quench already formed superoxide anion. As with chemotaxis inhibition, the fact that the tri-NAG prevents lysozyme suppression of triggered toxic oxygen radical production suggest that PMN membranes (and particularly their saccharide constituents) are the site of this lysozyme modulating activity as well.
Although the bacteriolytic activity of lysozyme has suggested that this enzyme is primarily involved in host bacterial defenses, we postulate that a different, and perhaps more important physiologic role is manifest by the enzyme-that of inflammation modulator. In this regard, we consider it likely that lysozyme is not the only modulating factor. Other substances at sites of inflammation, such as C5 fragments, platelets, oxidized lipids and so on, may have important effects as well. Conversely, it remains to be determined whether this proposed beneficial activity of lysozyme may become deleterious in patients with hyperlysozymemia, i.e., with sarcoidosis or monocytic leukemia (14, 43) . This possibility is suggested by the findings of Maderazo et al. (43) that PMN chemotaxis is suppressed in sarcoidosis, and by our own preliminary studies (12) that this chemotactic defect is corrected by adding tri-NAG to sarcoidosis plasma.
